palmitoylethanolamide + luteolin

Palmitoylethanolamide + luteolin is a combination therapeutic, frequently developed in a co-ultramicronized formulation, designed to target neuroinflammation and oxidative stress in central nervous system disorders. Palmitoylethanolamide (PEA) is an endogenous fatty acid amide that acts primarily as an agonist of the peroxisome proliferator-activated receptor-alpha (PPAR-alpha). By activating PPAR-alpha, PEA exerts Autacoid Local Injury Antagonism (ALIA) effects, which downregulate the activation of mast cells and microglia, thereby reducing the production of pro-inflammatory mediators. Luteolin is a flavonoid that provides complementary antioxidant activity and inhibits the production of pro-inflammatory cytokines such as TNF-alpha and IL-1beta. The combination is primarily investigated for neurodegenerative diseases, stroke recovery, and chronic pain, where it aims to restore homeostatic balance within the neurovascular unit and prevent glial cell overactivation.

Brand names

GlialiaPeaLutGliaPlex

Other names

PEA-Lutco-ultramicronized palmitoylethanolamide/luteolinmicronized palmitoylethanolamide + luteolin